259 followers
Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics | Clinical Cancer Research | American Association for Cancer Research https://t.co/sqEOBinZ0o
2,226 followers
RT @VivekSubbiah: @BenWestphalen @cjder23 @CR_AACR @OncoAlert @Aiims1742 @graokane @KenOliveLab @LyssiotisLab Clinical study here - @Dr_R_K…
5,343 followers
RT @VivekSubbiah: @BenWestphalen @cjder23 @CR_AACR @OncoAlert @Aiims1742 @graokane @KenOliveLab @LyssiotisLab Clinical study here - @Dr_R_K…
4,260 followers
RT @VivekSubbiah: @BenWestphalen @cjder23 @CR_AACR @OncoAlert @Aiims1742 @graokane @KenOliveLab @LyssiotisLab Clinical study here - @Dr_R_K…
33,594 followers
@BenWestphalen @cjder23 @CR_AACR @OncoAlert @Aiims1742 @graokane @KenOliveLab @LyssiotisLab Clinical study here - @Dr_R_Kurzrock Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics https://t.co/O2UVOOpihf
6,390 followers
RT @jacobadashek: NRAS + cell cycle altrns ORR 32.5% v only NRAS 10% (P < 0.014). Why would you give pts without cell cycle altrns a target…
4,260 followers
RT @jacobadashek: NRAS + cell cycle altrns ORR 32.5% v only NRAS 10% (P < 0.014). Why would you give pts without cell cycle altrns a target…
1,316 followers
RT @jacobadashek: NRAS + cell cycle altrns ORR 32.5% v only NRAS 10% (P < 0.014). Why would you give pts without cell cycle altrns a target…
624 followers
RT @jacobadashek: NRAS + cell cycle altrns ORR 32.5% v only NRAS 10% (P < 0.014). Why would you give pts without cell cycle altrns a target…
2,313 followers
RT @jacobadashek: NRAS + cell cycle altrns ORR 32.5% v only NRAS 10% (P < 0.014). Why would you give pts without cell cycle altrns a target…
3,111 followers
RT @jacobadashek: NRAS + cell cycle altrns ORR 32.5% v only NRAS 10% (P < 0.014). Why would you give pts without cell cycle altrns a target…
2,226 followers
NRAS + cell cycle altrns ORR 32.5% v only NRAS 10% (P < 0.014). Why would you give pts without cell cycle altrns a targeted drug to cell cycle altrns? Can someone explain? https://t.co/CcSKCuSi9h glad combo works here, classic case of missing the target
971 followers
RT @jacobadashek: COMBINATION APPROACH PARADIGM HAS BEEN VALIDATED IN SEVERAL STUDIES! I-PREDICT, MTB, CUP, and others https://t.co/gHL44NU…
2,552 followers
RT @jacobadashek: COMBINATION APPROACH PARADIGM HAS BEEN VALIDATED IN SEVERAL STUDIES! I-PREDICT, MTB, CUP, and others https://t.co/gHL44NU…
2,226 followers
COMBINATION APPROACH PARADIGM HAS BEEN VALIDATED IN SEVERAL STUDIES! I-PREDICT, MTB, CUP, and others https://t.co/gHL44NUCZh https://t.co/NYGiZZogiC https://t.co/h40RBSNsZz https://t.co/Nel17eccxw https://t.co/vpygjLk3JR https://t.co/57sUNvZdBu 5/8
2,226 followers
RT @FaltasLab: Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics https://t.co/COUfabXmnr
6,670 followers
Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics https://t.co/COUfabXmnr
34,499 followers
RT @PGrivasMDPhD: @OncoAlert
2,226 followers
RT @PGrivasMDPhD: @OncoAlert
2,226 followers
RT @benitezja: Great work showing that co inhibition of MEK and CDK4/6 shows clinical benefits
6,806 followers
RT @BenWestphalen: Fitting the preclinical data above ⬆️ @Dr_R_Kurzrock @jacobadashek & team in @CCR_AACR @OncoAlert 🚨#PrecisionMedicine…
2,226 followers
RT @BenWestphalen: Fitting the preclinical data above ⬆️ @Dr_R_Kurzrock @jacobadashek & team in @CCR_AACR @OncoAlert 🚨#PrecisionMedicine…
4,260 followers
Fitting the preclinical data above ⬆️ @Dr_R_Kurzrock @jacobadashek & team in @CCR_AACR @OncoAlert 🚨#PrecisionMedicine https://t.co/fUw38iCIkK
2,226 followers
RT @DrBenParsons: Great work @jacobadashek @Dr_R_Kurzrock @JasonSicklick could have a role in multiple tumor types. Would love to see this…
7,086 followers
RT @DrBenParsons: Great work @jacobadashek @Dr_R_Kurzrock @JasonSicklick could have a role in multiple tumor types. Would love to see this…
2,226 followers
4,260 followers
2,226 followers
RT @VivekSubbiah: Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics - PubMed https://t.co/M3n…
2,215 followers
RT @BenWestphalen: @RachelRiechelm2 @jordanberlin5 @GIcancerDoc @EileenMOReilly @SalemGIOncDoc I would go for the regime recently described…
3,111 followers
RT @VivekSubbiah: Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics - PubMed https://t.co/M3n…
852 followers
4,260 followers
@oncologician @UmutDisel @Dr_R_Kurzrock @SewantiLimaye @RAJATRAJ @SirohiBhawna @Aiims1742 As mentioned in the original thread; I would go for the regime of CDK4/6 inhibitor + MEK as described by Shumei Kato @Dr_R_Kurzrock & team. https://t.co/fUw38iC
4,260 followers
@RachelRiechelm2 @jordanberlin5 @GIcancerDoc @EileenMOReilly @SalemGIOncDoc I would go for the regime recently described by Shumei Kato @Dr_R_Kurzrock & colleagues. The data seems very promising. https://t.co/fUw38iCIkK
1,752 followers
@FogacciJoao @jordanberlin5 @GIcancerDoc @EileenMOReilly @SalemGIOncDoc @MPishvaian Agree palpo alone is ineffective. But I am proposing it together with trametinib. https://t.co/OblR8ted0k
33,594 followers
Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics - PubMed https://t.co/M3n8GNb6KR
6,806 followers
Co-targeting MEK and cyclin gene for advanced solid tumors. https://t.co/SVUdp7tLrJ https://t.co/qAj9uLOU1W
369 followers
Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics https://t.co/jEIYULH2KL
2,226 followers
RT @jacobadashek: Patients with concomitant Cyclin ➕ MAPK/MEK-related gene alterations🧬 benefit from combination approach‼️ Out today in @C…
1,504 followers
Concomitant targeting of parallel oncogenic pathways results in clinical benefit and tumor shrinkage. A strategy that makes sense and should be explored further. https://t.co/IaBE2XH2sV
1,374 followers
2,226 followers
6,806 followers
Co-targeting cyclin and MEK signaling can be successful when #tumors have genomic co-alterations that activate both of these pathways, Kato et al show. More studies to evaluate this precision strategy are needed. @UCSDHealth @jacobadashek @JasonSicklick
425 followers
RT @jacobadashek: Patients with concomitant Cyclin ➕ MAPK/MEK-related gene alterations🧬 benefit from combination approach‼️ Out today in @C…
372 followers
RT @jacobadashek: Patients with concomitant Cyclin ➕ MAPK/MEK-related gene alterations🧬 benefit from combination approach‼️ Out today in @C…
2,226 followers
RT @DrBenParsons: Great work @jacobadashek @Dr_R_Kurzrock @JasonSicklick could have a role in multiple tumor types. Would love to see this…
260 followers
Great work @jacobadashek @Dr_R_Kurzrock @JasonSicklick could have a role in multiple tumor types. Would love to see this as an arm in @theNCI MATCH
6,806 followers
RT @jacobadashek: Patients with concomitant Cyclin ➕ MAPK/MEK-related gene alterations🧬 benefit from combination approach‼️ Out today in @C…
2,226 followers
RT @benitezja: Great work showing that co inhibition of MEK and CDK4/6 shows clinical benefits
332 followers
RT @jacobadashek: Patients with concomitant Cyclin ➕ MAPK/MEK-related gene alterations🧬 benefit from combination approach‼️ Out today in @C…
152 followers
RT @jacobadashek: Patients with concomitant Cyclin ➕ MAPK/MEK-related gene alterations🧬 benefit from combination approach‼️ Out today in @C…
792 followers
RT @jacobadashek: Patients with concomitant Cyclin ➕ MAPK/MEK-related gene alterations🧬 benefit from combination approach‼️ Out today in @C…
34,499 followers
RT @jacobadashek: Patients with concomitant Cyclin ➕ MAPK/MEK-related gene alterations🧬 benefit from combination approach‼️ Out today in @C…
408 followers
RT @jacobadashek: Patients with concomitant Cyclin ➕ MAPK/MEK-related gene alterations🧬 benefit from combination approach‼️ Out today in @C…
912 followers
Great work showing that co inhibition of MEK and CDK4/6 shows clinical benefits
912 followers
RT @jacobadashek: Patients with concomitant Cyclin ➕ MAPK/MEK-related gene alterations🧬 benefit from combination approach‼️ Out today in @C…
639 followers
RT @jacobadashek: Patients with concomitant Cyclin ➕ MAPK/MEK-related gene alterations🧬 benefit from combination approach‼️ Out today in @C…
14,287 followers
RT @jacobadashek: Patients with concomitant Cyclin ➕ MAPK/MEK-related gene alterations🧬 benefit from combination approach‼️ Out today in @C…
11,018 followers
RT @jacobadashek: Patients with concomitant Cyclin ➕ MAPK/MEK-related gene alterations🧬 benefit from combination approach‼️ Out today in @C…
16,344 followers
RT @jacobadashek: Patients with concomitant Cyclin ➕ MAPK/MEK-related gene alterations🧬 benefit from combination approach‼️ Out today in @C…
14,111 followers
RT @jacobadashek: Patients with concomitant Cyclin ➕ MAPK/MEK-related gene alterations🧬 benefit from combination approach‼️ Out today in @C…
34,499 followers
16,344 followers
@OncoAlert
1,231 followers
RT @jacobadashek: Patients with concomitant Cyclin ➕ MAPK/MEK-related gene alterations🧬 benefit from combination approach‼️ Out today in @C…
3,142 followers
RT @jacobadashek: Patients with concomitant Cyclin ➕ MAPK/MEK-related gene alterations🧬 benefit from combination approach‼️ Out today in @C…
4,260 followers
RT @jacobadashek: Patients with concomitant Cyclin ➕ MAPK/MEK-related gene alterations🧬 benefit from combination approach‼️ Out today in @C…
7,086 followers
RT @jacobadashek: Patients with concomitant Cyclin ➕ MAPK/MEK-related gene alterations🧬 benefit from combination approach‼️ Out today in @C…
3,111 followers
RT @jacobadashek: Patients with concomitant Cyclin ➕ MAPK/MEK-related gene alterations🧬 benefit from combination approach‼️ Out today in @C…
2,226 followers
Patients with concomitant Cyclin ➕ MAPK/MEK-related gene alterations🧬 benefit from combination approach‼️ Out today in @CCR_AACR @AACR our paper led by @UCSDHealth @Dr_R_Kurzrock #ShumeiKato @JasonSicklick‼️ https://t.co/GGCDzUdh25 https://t.co/hShcO6lw1y
7,428 followers
Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics https://t.co/5VmsqGK9QI